<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR5">
 <label>5.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Francisca</surname>
    <given-names>RDC</given-names>
   </name>
   <name>
    <surname>Zomerdijk</surname>
    <given-names>IM</given-names>
   </name>
   <name>
    <surname>Sturkenboom</surname>
    <given-names>MCJM</given-names>
   </name>
   <name>
    <surname>Straus</surname>
    <given-names>SMJM</given-names>
   </name>
  </person-group>
  <article-title>Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures</article-title>
  <source>Expert Opin Drug Saf.</source>
  <year>2018</year>
  <volume>17</volume>
  <issue>10</issue>
  <fpage>975</fpage>
  <lpage>982</lpage>
  <pub-id pub-id-type="doi">10.1080/14740338.2018.1512579</pub-id>
  <pub-id pub-id-type="pmid">30107752</pub-id>
 </element-citation>
</ref>
